+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis Therapeutics Market by Therapeutic Class, Genotype, Route of Administration, Distribution Channel, Stage of Disease - Global Forecast to 2030- Product Image
Hepatitis Therapeutics Market by Therapeutic Class, Genotype, Route of Administration, Distribution Channel, Stage of Disease - Global Forecast to 2030- Product Image
Sale

Hepatitis Therapeutics Market by Therapeutic Class, Genotype, Route of Administration, Distribution Channel, Stage of Disease - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715892
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hepatitis therapeutics market is experiencing a period of structural evolution, shaped by advances in molecular therapeutics and shifting global healthcare priorities. Senior decision-makers must adapt to emerging care models, rising innovation, and regulatory complexities to achieve robust growth in a competitive sector.

Market Snapshot: Hepatitis Therapeutics Market Growth and Outlook

The Hepatitis Therapeutics Market grew from USD 30.76 billion in 2024 to USD 32.02 billion in 2025. It is projected to maintain a Compound Annual Growth Rate (CAGR) of 3.90%, reaching USD 38.72 billion by 2030. Market expansion is fueled by increasing adoption of targeted antiviral therapies, real-world evidence integration, and evolving reimbursement frameworks.

Scope & Segmentation

This report delivers a structured analysis of the hepatitis therapeutics market, mapping growth opportunities and evaluating risks across the value chain.

  • Therapeutic Classes: Combination therapies, direct acting antivirals (including NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors, pan-genotypic regimens), interferons, nucleotide analogues.
  • Genotypes: Genotype 1 (including 1A and 1B), 2, 3, 4, 5, and 6. Therapy selection is influenced by sub-genotypic response patterns.
  • Route of Administration: Oral, injectable (subcutaneous and intravenous). Modalities are aligned with patient acuity and setting of care.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, online pharmacies. Each channel addresses treatment continuity, convenience, and adherence differently.
  • Stage of Disease: Acute and chronic presentations, each with distinct therapeutic objectives focusing on viral clearance or long-term suppression.
  • Regional Coverage: Americas (United States including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Company Developments: Gilead Sciences, AbbVie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche, Novartis, Pfizer, GlaxoSmithKline, and Sanofi.

Key Takeaways for Senior Decision-Makers

  • Precision medicine and molecular diagnostics redefine patient stratification, enabling more effective and safer regimens tailored to specific viral genotypes.
  • The market is moving beyond monotherapy, with combination and pan-genotypic regimens becoming preferred for their efficacy across diverse patient groups and reduced resistance risks.
  • Integration of telemedicine and digital health tools enhances patient engagement, adherence tracking, and adverse event management, supporting both providers and payers.
  • Competition from cost-effective generics and biosimilars, particularly in emerging regions, is intensifying, making agility in pricing strategies and local partnerships vital.
  • Collaborations between global pharmaceutical firms and regional players accelerate market entry and widen patient access, especially in areas with high disease prevalence.
  • Stakeholders who prioritize real-world evidence and value-based contracting have an edge in securing favorable market access and formulary placement.

Tariff Impact: Navigating Supply Chain and Sourcing Challenges

Recent United States tariff adjustments have led to increased active pharmaceutical ingredient costs and heightened supply chain complexity. Manufacturers have responded by diversifying sourcing strategies, implementing dual-sourcing arrangements, and engaging regional contract manufacturers to stabilize supply and cost structures. Expedited customs clearance and increased buffer inventories have been adopted to ensure continuity of treatment delivery and mitigate risk exposure due to geopolitical shifts.

Methodology & Data Sources

This report integrates in-depth primary interviews with key opinion leaders, clinicians, payers, and supply chain experts, complemented by a structured clinician and procurement survey. Secondary research draws from medical journals, regulatory filings, clinical trial registries, and corporate disclosures. Analytical rigor was maintained through mixed-methods analysis, triangulation, and multi-phase expert validation.

Why This Report Matters for Strategic Planning

  • Enable investment and portfolio decisions by revealing actionable market segmentation, competitor positioning, and risk factors.
  • Support regulatory and market access strategies with region-specific, evidence-based insights tailored to payer and provider stakeholder priorities.
  • Empower clinical and commercial teams to integrate innovative therapeutics and digital solutions aligned with evolving standard of care.

Conclusion

The hepatitis therapeutics market is rapidly transforming, shaped by innovation, policy adjustments, and evolving patient needs. Organizations equipped with deep insight and adaptive strategy will be best positioned to advance clinical outcomes while sustaining commercial success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hepatitis Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Combination Therapies
8.3. Direct Acting Antivirals
8.3.1. Ns3/4A Protease Inhibitors
8.3.2. Ns5A Inhibitors
8.3.3. Ns5B Polymerase Inhibitors
8.3.4. Pan Genotypic Regimens
8.4. Interferons
8.5. Nucleotide Analogues
9. Hepatitis Therapeutics Market, by Genotype
9.1. Introduction
9.2. Genotype 1
9.2.1. Genotype 1A
9.2.2. Genotype 1B
9.3. Genotype 2
9.4. Genotype 3
9.5. Genotype 4
9.6. Genotype 5
9.7. Genotype 6
10. Hepatitis Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
11. Hepatitis Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Hepatitis Therapeutics Market, by Stage of Disease
12.1. Introduction
12.2. Acute
12.3. Chronic
13. Americas Hepatitis Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hepatitis Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hepatitis Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. Merck & Co., Inc.
16.3.4. Bristol-Myers Squibb Company
16.3.5. Johnson & Johnson
16.3.6. F. Hoffmann-La Roche Ltd
16.3.7. Novartis AG
16.3.8. Pfizer Inc.
16.3.9. GlaxoSmithKline plc
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEPATITIS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. HEPATITIS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. HEPATITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 59. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 61. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 63. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 69. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 110. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 118. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 130. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 132. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 134. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 136. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 142. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 144. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 170. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 174. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 186. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 187. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 188. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 190. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 192. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 198. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 222. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 224. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 230. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 232. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 246. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 250. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 252. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 253. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 254. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 275. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 276. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 277. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 278. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 279. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 281. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 283. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 284. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 285. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 286. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 287. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 289. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 294. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 295. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 297. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 323. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 324. THAILAND HEPATITIS THERAPEUTICS MARKET

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hepatitis Therapeutics market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 32.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.72 Billion
Compound Annual Growth Rate3.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hepatitis Therapeutics - Global Strategic Business Report - Product Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Image

Hepatitis C Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Hepatitis Therapeutics Market Report 2025 - Product Image

Hepatitis Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Alcoholic Hepatitis Treatment - Global Strategic Business Report - Product Image

Alcoholic Hepatitis Treatment - Global Strategic Business Report

  • Report
  • 265 Pages
  • Global
From

About the Hepatitis Drug Market

The Hepatitis Drug market is a subset of the Infectious Diseases Drugs market, which includes treatments for a variety of illnesses caused by microorganisms. Hepatitis drugs are used to treat viral infections of the liver, including hepatitis A, B, and C. These drugs can be used to reduce symptoms, prevent further damage to the liver, and even cure the infection. Common treatments include antiviral medications, interferon, and direct-acting antivirals. The Hepatitis Drug market is highly competitive, with many companies offering treatments for different types of hepatitis. Some of the major players in the market include AbbVie, Gilead Sciences, Merck, Bristol-Myers Squibb, and Novartis. Other companies such as Cipla, Mylan, and Teva Pharmaceuticals also offer treatments for hepatitis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.